Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $27.00

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has received a consensus recommendation of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $27.00.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th.

Olema Pharmaceuticals Stock Down 2.7 %

Olema Pharmaceuticals stock opened at $6.15 on Friday. Olema Pharmaceuticals has a 12 month low of $5.56 and a 12 month high of $16.77. The company’s fifty day simple moving average is $9.59 and its 200-day simple moving average is $11.46. The stock has a market cap of $352.38 million, a P/E ratio of -2.81 and a beta of 1.92.

Insider Buying and Selling at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, CEO Sean Bohen sold 52,328 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $490,313.36. Following the completion of the sale, the chief executive officer now owns 298,836 shares of the company’s stock, valued at $2,800,093.32. This represents a 14.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David C. Myles sold 12,452 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.38, for a total value of $116,799.76. Following the transaction, the insider now owns 611,947 shares in the company, valued at approximately $5,740,062.86. This trade represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 773,797 shares of company stock worth $5,414,609 over the last three months. Corporate insiders own 19.40% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Large investors have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth $34,753,000. Great Point Partners LLC acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth about $8,622,000. Candriam S.C.A. boosted its stake in Olema Pharmaceuticals by 199.9% during the 2nd quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock valued at $11,454,000 after purchasing an additional 705,655 shares during the period. Affinity Asset Advisors LLC bought a new stake in Olema Pharmaceuticals during the 2nd quarter valued at approximately $2,976,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after buying an additional 207,565 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.